Residual tumor after the salvage surgery is the major risk factors for primary treatment failure in malignant ovarian germ cell tumors: A retrospective study of single institution

Table 3 Summary of clinicopathologic features, treatment, and outcome of those who failed primary treatment

Pt's ID	Age	Histology/Stage	Primary treatment	Outcome of primary treatment	Time to relapse (months)	Site of Relapse/ progression	Salvage treatment	Outcome
1	18	Choriocarcinoma/ Stage IV	TAH + BSO + staging op + BEP chemo.	CR	4	Brain	EMA-CO chemo.	DOD
2	25	Immature teratoma/ Stage Ic	USO + staging op	CR	11	PAN	BEP chemo	NED at age 33
3	22	Mixed germ cell tumor/Stage IIIa	TAH + BSO + staging op + EP chemo	CR	12	Mesentery	EP chemo	NED at age 33
4	19	EST/Stage IIIa	TAH + BSO + staging op + CP chemo.	CR	7	Mesentery	EP chemo.	NED at age 29
5	29	EST/Stage IIIc	TAH + BSO + staging op + EP chemo.	CR	6	Pelvic lymph node	VBP chemo.	NED at age 36
6	65	Mixed germ cell tumor/Stage IIIc	TAH + BSO + staging op + EP chemo	Progressi-on		Liver	Cisplatin + Paclitaxel chemo.	DOD

TAH, total abdominal hysterectomy; BSO, bilateral salpingo-oophorectomy; USO, unilateral salpingo-oophorectomy; EMA-CO, etoposide, methotraxate, actinomycin-D, vincristine, and cyclophosphamide; BEP, bleomycin, etoposide, and cisplatin; EP, etoposide and cisplatin; CP, cisplatin and cyclophophamide; VBP, vinblastine, bleomycin, and cisplatin; CR, complete remission; PAN, paraaortic lymph node; DOD, died of disease; NED, no evidence of disease.

ISSN: 1477-7819